Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy

Human malignant melanoma has poor prognosis because of resistance to apoptosis and therapy. We describe identification of the expression profile of 1,037 mitochondria-focused genes and 84 survival-apoptosis genes in 21 malignant melanoma cell lines and 3 normal melanocyte controls using recently developed hMitChip3 cDNA microarrays. Unsupervised hierarchical clustering analysis of 1,037 informative genes, and 84 survival-apoptosis genes, classified these malignant melanoma cell lines into type A (n = 12) and type B (n = 9). Three hundred fifty-five of 1,037 (34.2%) genes displayed significant (P ≤ 0.030; false discovery rate ≤ 3.68%) differences (±≥2.0-fold) in average expression, with 197 genes higher and 158 genes lower in type A than in type B. Of 84 genes with known survival-apoptosis functions, 38 (45.2%) displayed the significant (P < 0.001; false discovery rate < 0.15%) difference. Antiapoptotic (BCL2, BCL2A1, PPARD, and RAF1), antioxidant (MT3, PRDX5, PRDX3, GPX4, GLRX2, and GSR), and proapoptotic (BAD, BNIP1, APAF1, BNIP3L, CASP7, CYCS, CASP1, and VDAC1) genes expressed at higher levels in type A than in type B, whereas the different set of antiapoptotic (PSEN1, PPP2CA, API5, PPP2R1B, PPP2R1A, and FIS1), antioxidant (HSPD1, GSS, SOD1, ATOX1, and CAT), and proapoptotic (ENDOG, BAK1, CASP2, CASP4, PDCD5, HTRA2, SEPT4, TNFSF10, and PRODH) genes expressed at lower levels in type A than in type B. Microarray data were validated by quantitative reverse transcription-PCR. These results showed the presence of two types of malignant melanoma, each with a specific set of dysregulated survival-apoptosis genes, which may prove useful for development of new molecular targets for therapeutic intervention and novel diagnostic biomarkers for treatment and prognosis of malignant melanoma.[Mol Cancer Ther 2009;8(5):OF1–13]

[1]  R. Abramson,et al.  Detection of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of Thermus aquaticus DNA polymerase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[2]  G. A. Whitmore,et al.  Importance of replication in microarray gene expression studies: statistical methods and evidence from repetitive cDNA hybridizations. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[3]  A. Hauschild,et al.  Systemic therapy for metastatic malignant melanoma – from deeply disappointing to bright future? , 2008, Experimental dermatology.

[4]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[5]  J M Trent,et al.  Tumorigenicity in human melanoma cell lines controlled by introduction of human chromosome 6. , 1990, Science.

[6]  M. Herlyn,et al.  Molecular events in melanoma development and progression. , 1998, Frontiers in bioscience : a journal and virtual library.

[7]  E. Seftor,et al.  Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line , 1991, International journal of cancer.

[8]  M. Nicolson,et al.  Melanoma incidence and mortality in Scotland 1979–2003 , 2007, British Journal of Cancer.

[9]  Yan A. Su,et al.  Molecular mechanism underlying differential apoptosis between human melanoma cell lines UACC903 and UACC903(+6) revealed by mitochondria-focused cDNA microarrays , 2008, Apoptosis.

[10]  Yan A. Su,et al.  Third-generation human mitochondria-focused cDNA microarray and its bioinformatic tools for analysis of gene expression. , 2007, BioTechniques.

[11]  U. G. Dailey.  Cancer,Facts and Figures about. , 2022, Journal of the National Medical Association.

[12]  C. Garbe,et al.  Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. , 2003, The Lancet. Oncology.

[13]  M. Lens,et al.  Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma , 2004, The British journal of dermatology.

[14]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[15]  P. Meltzer,et al.  Reversion of monochromosome-mediated suppression of tumorigenicity in malignant melanoma by retroviral transduction. , 1996, Cancer research.

[16]  U. Schumacher,et al.  Clinically proven markers of metastasis predict metastatic spread of human melanoma cells engrafted in scid mice , 2007, British Journal of Cancer.

[17]  J. Eberle,et al.  Apoptosis pathways as promising targets for skin cancer therapy , 2007, The British journal of dermatology.

[18]  N. Kieffer,et al.  Up‐regulated expression of the β3 integrin and the 92‐kDa gelatinase in human HT‐144 melanoma cell tumors grown in nude mice , 1996, International journal of cancer.

[19]  J. Eberle,et al.  Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[20]  Yan A. Su,et al.  Identification of Tumor‐Suppressor Genes Using Human Melanoma Cell Lines UACC903, UACC903(+6), and SRS3 by Comparison of Expression Profiles , 2000, Molecular carcinogenesis.

[21]  R. Marais,et al.  Melanoma biology and new targeted therapy , 2007, Nature.

[22]  L Edler,et al.  Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  M. Bar‐eli,et al.  Abnormalities in the CDKN2 (p16INK4/MTS-1) gene in human melanoma cells: relevance to tumor growth and metastasis. , 1995, Oncogene.

[24]  T. Golub,et al.  Modeling genomic diversity and tumor dependency in malignant melanoma. , 2008, Cancer research.

[25]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Yan A. Su,et al.  Monoamine oxidase‐A is a major target gene for glucocorticoids in human skeletal muscle cells , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  E. Schmitt,et al.  Dendritic Cell‐Based Immunotherapy of Malignant Melanoma: Success and Limitations , 2007, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[28]  P. Meltzer,et al.  Molecular determinants of human uveal melanoma invasion and metastasis , 2004, Clinical & Experimental Metastasis.

[29]  Yan A. Su,et al.  Differences in Apoptosis and Cell Cycle Distribution between Human Melanoma Cell Lines UACC903 and UACC903(+6), before and after UV Irradiation , 2007, International journal of biological sciences.

[30]  K. Tanabe,et al.  The role of apoptosis in cancer cell survival and therapeutic outcome , 2006, Cancer biology & therapy.

[31]  A. Blum,et al.  Epidemiology of Cutaneous Melanoma in Germany and Worldwide , 2001, Skin Pharmacology and Physiology.

[32]  H. Pehamberger,et al.  Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  D. Schadendorf,et al.  Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  S. Lowe,et al.  Apoptosis and melanoma chemoresistance , 2003, Oncogene.

[35]  Y. Ohta,et al.  S100A4 expression with reduced E-cadherin expression predicts distant metastasis of human malignant melanoma cell lines in the NOD/SCID/gammaCnull (NOG) mouse model. , 2005, Oncology Report.